Home » Onderzoek – Themapagina » Overzicht richtlijnen, recente literatuur

  1. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 61
  2. Addison T.On the Constitutional and Local Effects of Disease of the Supra-renal Capsules. London, UK: Samuel Highley; 1855.
  3. Pearce J; Thomas Addison (1793-1860). J R Soc Med 2004 97 297-300
  4. Jeffcoate W; Thomas Addison: one of the three “Giants”of Guy’s Hospital. Lancet 2005 365 1989-1990
  5. Graner J; Addison, pernicious anemia and adrenal insufficiency. Can Med Assoc J 1985 133 855-923
  6. Encyclopedia of World Biography on Thomas Addison 1-9
  7. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 127
  8. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 190
  9. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 260
  10. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 130
  11. Hiatt JR, Hiatt N; The conquest of Addison’s disease. Am J Surgery 1997 174(3) 280-283
  12. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 183
  13. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 261
  14. Medvei VC 1993 The History of Clinical Endocrinology: Comprehensive Account of Endocrinology from earliest times to the present day 2Rev. ed UK The Parthenon Publishing Group Limited, page 262
  15. Graham G; Discussion on the treatment of Addison’s disease with salt. Proc Royal Soc Med 1936 XXIX 1137-1145
  16. Coursin DB, Wood KE; Corticosteroid supplementation for adrenal insufficiency. JAMA 2002 287(2) 236-240
  17. Arlt W, Allolio B; Adrenal insufficiency. Lancet 2003 361 1881-1893
  18. Løvås K, Husebye ES; Replacement therapy for Addison’s disease: recent developments. Expert Opin Investig Drugs 2008 17(4) 497-509
  19. Hahner S, Allolio B; Therapeutic management of adrenal insufficiency. Best Practice & Res Clin Endocrinol & Metab 2009 23 167-179
  20. Arlt W; The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab 2009 94 1059-1067
  21. Crown A, Lightman S; Why is management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol 2005 63 483-492
  22. Debono M, Ross RJ, Newell-Price J; Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009 160 719-729
  23. Reisch N, Arlt W; Fine tuning for quality of life: 21st century approach to treatment of Addison’s disease. Endocrinol Metab Clin North Am 2009 38(2) 407-418
  24. Lennernäs H, Skrtic S, Johannsson G; Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opin Drug Metab Toxicol 2008 4(6) 749-758
  25. Løvås K, Loge JH, Husebye ES; Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol 2002 56 581-588
  26. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W, Allolio B; Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007 92 3912-3922
  27. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G; Premature Mortality in Patients with Addison’s Disease: A Population-Based Study. J Clin Endocrinol Metab 2006 91 4849-4853
  28. Bensing S, Brandt L, Tabaroj F, Sjöberg O, Nilsson B, Ekbom A, Blomqvist P, Kämpe O; Increased death risk and altered cancer incidence pattern in patients with isolated or combined auto-immune primary adrenocortical insufficiency. Clin Endocrinol 2008 69 697-704
  29. Erichsen MM, Løvås K, Fougner KJ, Svartberg J, Hauge ER, Bollerslev J, Berg JP, Mella B, Husebye ES; Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol 2009 160 233-237
  30. Jacobson L; Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol Metab Clin North Am 2005 34(2) 271-292
  31. Greenspan; Basic and Clinical Endocrinology
  32. Seralini GE; Regulation factors of corticosteroid-binding globulin: lesson from ontogenesis. Horm Res 1996 45(3-5) 192-196
  33. Hammond GL, Smith CL, Underhill DA; Molecular studies of corticosteroid binding globulin structure, biosynthesis and function. J Steroid Biochem Mol Biol 1991 40(4-6) 755-762
  34. Seckl J, Walker B; Minireview: 11-beta-hydroxysteroid dehydrogenase type-1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001 142 1371-1376
  35. Tomlinson J, Walker E, Bujalska I, Draper N, Lavery G, Cooper G, Hewison M, Stewart P; 11-beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews 2004 25 831-866
  36. Seckl J, Chapman K; The 11-beta-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action. Eur J Biochem 1997 249 361-364
  37. Tasker JG, Di S, Malcher-Lopes R; Minireview: rapid glucocorticoid signalling via membrane-associated receptors. Endocrinology 2006 147(12) 5549-5556
  38. Stahn C, Buttgereit F; Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008 4(10) 525-533
  39. Desvergne B, Héligon C; Steroid hormone pulsing drives cyclic gene expression; Nature Cell Biology 2009; 11(9):1051-1053
  40. Ebrecht M, Buske-Kirschbaum A, Hellhammer D, Kern S, Rohleder N, Walker B, Kirschbaum C. Tissue specificity of glucocorticoid sensitivity in healthy adults. J Clin Endocrinol Metab 2000 85 3733-3739
  41. Chriguer RS, Elias LL, da Silva IM, Vieira JG, Moreira AC, Castro M; Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies. J Clin Endocrinol Metab 2005 90 5978-5984
  42. Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M; Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991 31 473-476
  43. Heazelwood VJ, Galligan JP, Cannell GR, Bochner F, Mortimer RH; Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. Br J Clin Pharmacol 1984 17 55-59
  44. Khalid BAK, Burke CW, Hurley DM, Funder JW, Stockigt JR; Steroid replacement in Addison’s disease and in subjects adrenalectomized for Cushing’s disease: Comparison of various glucocorticoids. JCEM 1982 55(3) 551-559
  45. Suliman AM, Freaney R, Smith TP; The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency; Clin Endocrinol 2003 59 380-387
  46. Bleicken B, Hahner S, Loeffler M; Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency; Clin Endocrinol 2010 72 297-304
  47. Esteban N, Loughlin T, Yergey A et al; Daily cortisol production rate in man determined by stable isotope dilution / mass spectrometry; JCEM 1991 71 39-45
  48. Kerrigan JR, Veldhuis JD, Leyo SA, Iramanesh A, Rogol AD; Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis JCEM 1993 76 1505-1510
  49. Brandon DD, Isabelle LM, Samuels MH, Kendall JW, Loriaux DL; Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids 1999 64 372-378
  50. Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM, De Bruin R; The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. JCEM 1998 83 1247-1252
  51. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ; Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency Clin Endocrinol 2004 61(3) 367-75
  52. Peacy SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP; Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol 1997 46(3) 255-261
  53. Howlet TA; An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol 1997 46(3) 263-268
  54. Wichers M, Springer W, Bidlingmaier F, Klingmüller D; The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin Endocrinol 1999 50(6) 759-765
  55. Hermus AR, Zelissen PM; Diagnosis and therapy of patients with adrenocortical insufficiency. Ned Tijdschr Geneeskd 1998 142(17) 944-999
  56. Behan LA, Rogers B, Hannon MJ, O’Kelly P, Tormey W, Smith D, Thompson CJ, Agha A; Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients Clin Endocrinol 2011 75(4) 505-13
  57. Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L; Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. JCEM 1971 33 14-22
  58. Chrousos G; Ultradian, circadian and stress-related hypothalamic-pituitary-adrenal axis activity- a dynamic digital-to-analog modulation. Endocrinology 1998 139 437-439
  59. Riedel M, Wiese A, Schurmeyer TH, Brabant G; Quality of life in patients with Addison’s disease: effects of different cortisol replacement modes; Experimental and Clinical Endocrinology 1993 101 106-111
  60. Bleicken B, Hahner S, Loeffler M; Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency; Clin Endocrinol 2010 72 297-304
  61. Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A, Sanmarti A; Evaluation of two replacement regimes in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters; J Endocrinol Invest 2004 27(5) 449-454
  62. Barbetta L, Dall’ Asta C, Re T, Libè R, Costa E, Ambrosi B; Comparison of different regimes of glucocorticoid replacement therapy in patients with hypoadrenalism; J Endocrinol Invest 2005 28(7) 632-637
  63. Laureti S, Falorni A, Santeusanio F; Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses; J Endocrinol Invest 2003 26 1071-1075
  64. Groves RW, Toms GC, Houghton BJ, Monson JP; Corticosteroid replacement therapy: twice or thrice daily? J Royal Soc Med 1988 81 514-516
  65. Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C; Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet 2010 49(7) 455-463
  66. Ekman B, Bachrach-Lindström, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ; A randomized double blind crossover study comparing two and four dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol 2012 Jan 30
  67. Ekman B, Blomgren J, Andersson PO, Carlsson M, Arnqvist HJ; Variable sensitivity to the glucocorticoid activity of cortisol in patients with primary adrenal insufficiency: assessment with ACTH profiles. Horm Metab Res 2010 42(13) 961-966
  68. Trainer PJ, McHardy KC, Harvy RD, Reid IW; Urinary free cortisol in the assessment of hydrocortisone replacement therapy. Horm Metab Res 1993 25(2) 117-120
  69. Kley HK, Krüskemper HL; Cortisol-Substitution bei nebennierenrindeninsuffizienz: Individuelle dosierung in abhängigkeit vom plasmaspiegel. Deutsche Medizinische Wochenschrift 1978 4 155-161
  70. Scott RS, Donald RA, Espiner EA; Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin Endocrinol 1978 9 571-576
  71. Arlt W, Rosenthal C, Hahner S, Allolio B; Quality of glucocorticoid replacement in adrenal insufficiency: clinical vs. timed serum cortisol measurements. Clin Endocrinol 2006 64 384-389
  72. Lovas K, Thorsen TE, Husebye ES; Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison’s disease. J Endocrinol Invest 2006 29(8) 727-731
  73. C.C.J. Smans, E.G.W.M.Lentjes, A.R.M.M. Hermus, P.M.J.Zelissen; Optimizing glucocorticoid replacement therapy in Addison’s disease: The value of salivary cortisol day curves . Submitted
  74. Gow R, Koren G, Rieder M, Van Uum S; Hair cortisol content in patients with adrenal insufficiency on hydrocortisone replacement therapy. Clin Endocrinol 2011 74 687-693
  75. Jadoul M, Ferrant A, De Plaen, Crabbé J; Mineralocorticoids in the management of primary adrenocortical insufficiency. J Endocrinol Invest 1991 14(2) 87-91
  76. Smith SJ, MacGregor GA, Markandu ND, Bayliss J, Banks RA, Prentice MG, Dorrington-Ward P, Wise P; Evidence that patients with Addison’s disease are undertreated with fludrocortisone. Lancet 1984 1 11-14
  77. Flad TM, Conway JD, Cunningham SK, McKenna TJ; The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol 1996 45(5) 529-534
  78. Flynn MD, Shore AC, Sandeman DE, Mawson D, Donohoe M, Tooke JE; Oedema in patients with Addison’s disease on replacement therapy: glucocorticoid excess and mineralocorticoid deficiency? QJM 1994 87(7) 437-441
  79. Oelkers W, Diederich S, Bahr V; Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. JCEM 1992 75(1) 259-264
  80. Arlt W; Dehydroepiandrosterone replacement therapy. Seminars in Reproductive Medicine 2004 22(4) 379-388
  81. Bhagra S, Nippoldt TB, Nair KS; Dehydroepiandrosterone in adrenal insufficiency and ageing. Curr Opin Endocrinol Diabetes Obes 2008 15 239-243
  82. Arlt W, Callies F, Vlijmen JC van, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B; Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999 341 1013-1020
  83. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK; Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000 85(12) 4650-6
  84. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VKK; Long-term DHEA replacement in primary adrenal insufficiency: A randomized, controlled trial. J Clin Endocrinol Metab 2008 93 400-409
  85. Dhatariya KK, Greenlund LJ, Bigelow ML, Thapa P, Oberg AL, Ford GC, Schimke JM, Nair KS; Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clin Proc. 2008 83(11) 1218-25
  86. Callies F, Fassnacht M, Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B; Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab. 2001 86(5) 1968-72
  87. Løvås K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebø BG, Myking OL, Kämpe O, Husebye ES; Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab. 2003 88(3) 1112-8
  88. Gebre-Medhin G, Husebye ES, Mallmin H, Helström L, Berne C, Karlsson FA, Kämpe O; Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison’s disease. Clin Endocrinol 2000 52(6) 775-80
  89. Christiansen JJ, Hojberg Gravholt, Fisker S, Moller N, Andersen M, Svenstrup B, Bennett P, Ivarsen P, Christiansen JS, Jorgensen JOL; Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. EJE 2005 152 77-85
  90. Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, Montori M; A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials of DHEA Treatment Effects on Quality of Life in Women with adrenal insufficiency. JCEM 2009 94 3676
  91. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ; Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol 2006 65 45-50
  92. Lovas K, Husebye ES; Continuous subcutaneous hydrocortisone infusion in Addison’s disease. EJE 2007 157 109-112
  93. Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ; Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol 2008 68 130-13
  94. Debono M, Ghobadi C, Rostami-Hodjegan A,Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ; Modified-Release Hydrocortisone to Provide Circadian Cortisol Profiles. JCEM 2009 94(5) 1548–1554
  95. Johannsson G, Bergthorsdottir, Nilsson AG, Lennernas H, Hedner T, Skrtic S; Improved glucocorticoid replacement therapy using a novel modified release hydrocortisone tablet: a pharmacokinetic study. EJE 2009 161 119-130
  96. Verma S, VanRyzin C, Sinaii N, Kim MS, Nieman LK, Rivindran S, Calis KA, Arlt W, Ross RJ, Merke DP; A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (ChronocortTM) versus conventional hydrocortisone (CortefTM) in the treatment of Congenital adrenal hyperplasia. Clin Endocrinol 2010 72(4) 441-447
  97. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BMK, Monson JP, Stewart PM, Lennernäs, Skrtic S; Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. JCEM 2012 97 473-481

Bron: Addison’s disease, Challenges in treatment and follow up, L.C.C.J.Smans, 2015
Geplaatst: 13 oktober 2016